New indications for Tremfya (guselkumab) can broaden who is technically eligible, but exact eligibility depends on the specific indication language in the FDA label and on payer policies. Here’s how it typically plays out:
- Disease and population: Each indication defines which patients and which diseases qualify (e.g., plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, etc.). An expanded indication means more patients with that condition may be eligible.
- Age and baseline criteria: Some indications specify an age range (e.g., adults 18+ or, less commonly, younger ages) and may require certain disease activity levels or severity (for example, PASI scores for psoriasis, joint involvement or enthesitis for PsA, BASDAI/ASDAS scores for axial SpA).
- Prior therapies: Many indications specify whether prior therapy is required (e.g., inadequate response to one or more conventional systemic therapies, DMARDs, or TNF inhibitors). Others may allow use as a first-line biologic depending on the label.
- Safety and screening prerequisites: Regardless of indication, patients must meet safety criteria (current infections, TB screening status, hepatitis B precautions, vaccination status, pregnancy considerations, etc.).
- Insurance and access: Payers often require prior authorization and may impose their own criteria or step therapy even if a patient technically meets the FDA label. Coverage can vary by indication and region.
What to do next:
- Check the current Tremfya label for the exact indication you’re asking about, including (if applicable) age, disease activity thresholds, and any prior therapy requirements.
- Confirm with the prescriber whether the patient meets those, and discuss any safety screenings needed (TB test, hepatitis B status, vaccinations).
- Contact the patient’s insurer or review the formulary to understand required prior authorization and any step-therapy rules.
- If you tell me which specific new indication you’re referring to (or share a link to the label), I can summarize the exact criteria and typical coverage considerations for that indication.
If you want, describe the new indication you have in mind and I’ll tailor the eligibility guidance to that use case.